keyword
MENU ▼
Read by QxMD icon Read
search

HOPE-3

keyword
https://www.readbyqxmd.com/read/29019063/statin-prescribing-in-the-elderly-special-considerations
#1
REVIEW
M Leya, N J Stone
PURPOSE OF REVIEW: Our aim was to examine the current evidence behind prescribing statins to individuals over 65 years of age with emphasis on those older than 75. Individuals over 75 years of age may often have multiple comorbidities and take many medications. Additionally, they are often underrepresented in randomized controlled trials (RCTs) of statins in older populations. While results of RCTs demonstrate the benefit of statin therapy in both primary and secondary prevention patients, clinicians must more carefully consider adverse effects and drug-drug interactions before prescribing statin therapy as well as determining the intensity in older individuals...
October 11, 2017: Current Atherosclerosis Reports
https://www.readbyqxmd.com/read/28938505/-treatment-targets-in-hypertension
#2
Rainer Düsing
The optimal target blood pressure (BP) in the treatment of hypertensive patients remains controversial. Recently, the systolic blood pressure trial (SPRINT) has proposed that a target systolic blood pressure of < 120 mmHg provides prognostic benefit in elderly hypertensive patients at high cardiovascular risk. The results of SPRINT contrast with several other intervention trials which have investigated the effect of intense BP lowering (Secondary Prevention of Small Subcortical Strokes [SPS3], Action to Control Cardiovascular Risk in Diabetes [ACCORD], Heart Outcomes Prevention Evaluation [HOPE]-3)...
September 2017: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/28748919/changing-concepts-in-hypertension-management
#3
REVIEW
P S Gudsoorkar, S W Tobe
Hypertension is the most common modifiable risk factor for cardiovascular disease and death, and lowering blood pressure with anti-hypertensive drugs reduces target organ damage and prevents cardiovascular disease outcomes. The recent trials SPRINT and HOPE-3 will lead to changes in the way we manage hypertension and impact on clinical practice guidelines. These studies also demonstrate the shift toward automated blood pressure measurements. We have reviewed these studies and others to put them in context with the guidelines that have come before and to describe how they will impact on hypertension treatment thresholds and targets, the treatment of hypertension in the elderly, and changing approaches to the management of hypertension including resistant hypertension...
July 27, 2017: Journal of Human Hypertension
https://www.readbyqxmd.com/read/28726432/-news-in-the-treatment-of-hypertension-and-dyslipidemia
#4
Jan Václavík
These review article presents the results of major recent studies in cardiovascular prevention. HOPE-3 study showed that people with medium cardiovascular risk who have not experienced a cardiovascular event, and have normal blood pressure, benefit from deploying a statin, and in the presence of hypertension benefit from deploying a combination of a statin and antihypertensive drugs. Studies evaluating genetic predisposition brought new evidence that both LDL cholesterol and systolic blood pressure are independent and multiplicative causal risk factors for cardiovascular events...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/28706171/-hermeneutic-phenomenological-study-on-caring-experience-of-spouses-of-elderly-people-with-dementia-at-home
#5
Hye Young Jang, Myungsun Yi
PURPOSE: This study aimed to understand and describe the caring experiences of spouses of elderly people with dementia. METHODS: The hermeneutic phenomenological method was used and participants were 12 spouses aged 65 and over who were taking care of their husbands or wives with dementia at home. Data were collected from individual in-depth interviews on participants' actual caring experiences. Additionally, novels, movies, and memoirs on elderly couples with partner who had dementia were included as data for the analysis...
June 2017: Journal of Korean Academy of Nursing
https://www.readbyqxmd.com/read/28634218/high-quality-statin-trials-support-the-2013-acc-aha-cholesterol-guidelines-after-hope-3-the-multi-ethnic-study-of-atherosclerosis
#6
Martin B Mortensen, Matthew J Budoff, Dong Li, Khurram Nasir, Michael J Blaha, Veit Sandfort, Carlos J Rodriguez, Pamela Ouyang, Erling Falk
The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guideline on cholesterol treatment to prevent atherosclerotic cardiovascular disease (ASCVD) has been criticized for lowering the risk thresholds for primary prevention with statin therapy. Although the ≥ 7.5% (class I) and ≥ 5% (class IIa) 10-year ASCVD risk thresholds were identified as new indications for treatment by extrapolating results obtained in randomized controlled trials (RCT) of statin therapy, results from population-based European cohorts indicate that >30% of individuals eligible for statin therapy by class I recommendations do not have RCT data supporting statin efficacy...
June 20, 2017: Circulation
https://www.readbyqxmd.com/read/28385949/primary-prevention-with-statin-therapy-in-the-elderly-new-meta-analyses-from-the-contemporary-jupiter-and-hope-3-randomized-trials
#7
LETTER
Paul M Ridker, Eva Lonn, Nina P Paynter, Robert Glynn, Salim Yusuf
No abstract text is available yet for this article.
May 16, 2017: Circulation
https://www.readbyqxmd.com/read/28331550/experiences-of-mobility-for-people-living-with-rheumatoid-arthritis-who-are-receiving-biologic-drug-therapy-implications-for-podiatry-services
#8
Lucy Sanders, Margaret Donovan-Hall, Alan Borthwick, Catherine J Bowen
BACKGROUND: Despite significant advancements in new treatment modalities for rheumatoid arthritis with biological therapies, foot complications remain a disabling and common feature of the disease. In this study the aim was to explore and describe the personal experiences of people with rheumatoid arthritis in receipt of biologic treatments in a bid to understand the impact of this form of medication on their mobility. METHODS: An interpretative phenomenological analysis (IPA) was undertaken to explore in depth the individual experience of rheumatoid disease through personal accounts of the patient journey spanning both 'before' and 'after' the instigation of biologic therapy...
2017: Journal of Foot and Ankle Research
https://www.readbyqxmd.com/read/28288682/low-disease-activity-for-up-to-3%C3%A2-years-after-adalimumab-discontinuation-in-patients-with-early-rheumatoid-arthritis-2-year-results-of-the-hopeful-3-study
#9
Yoshiya Tanaka, Hisashi Yamanaka, Naoki Ishiguro, Nobuyuki Miyasaka, Katsuyoshi Kawana, Junko Kimura, Naoki Agata, Tsutomu Takeuchi
BACKGROUND: This study was conducted to evaluate the feasibility of long-term adalimumab (ADA) discontinuation after achievement of low disease activity (LDA) in Japanese patients with early rheumatoid arthritis (RA) and to identify predictors of LDA maintenance. METHODS: In the HOPEFUL-1 study, patients received initial therapy with either ADA plus methotrexate (MTX; intensive therapy) or MTX alone (standard therapy) for 26 weeks, followed by ADA + MTX for 26 weeks...
March 14, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28278329/patients-and-parents-needs-attitudes-and-perceptions-about-early-palliative-care-integration-in-pediatric-oncology
#10
MULTICENTER STUDY
Deena R Levine, Belinda N Mandrell, April Sykes, Michele Pritchard, Deborah Gibson, Heather J Symons, David Wendler, Justin N Baker
Importance: Early palliative care integration for cancer patients is now touted as the optimal care model, yet significant barriers often prevent its implementation. A perceived barrier, especially for pediatric oncology patients, is the notion that patients and their families may not need or want palliative care involvement early in the disease trajectory. Objective: To determine the perception of symptom burden early in treatment and assess attitudes toward early integration of palliative care in pediatric oncology patient-parent pairs...
September 1, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28030456/the-heart-outcomes-prevention-evaluation-hope-3-trial-where-do-we-stand
#11
Niki Katsiki, Dimitri P Mikhailidis, Costas Tsioufis
No abstract text is available yet for this article.
February 2017: Current Opinion in Lipidology
https://www.readbyqxmd.com/read/28010010/hope-%C3%A2-3-bp-treatment-milestones-in-cv-prevention-dr-salim-yusuf-in-an%C3%A2-interview-with-dr-akbar-panju-and-dr-roman-jaeschke
#12
Salim Yusuf, Akbar Panju, Roman Jaeschke
No abstract text is available yet for this article.
December 23, 2016: Polskie Archiwum Medycyny Wewnętrznej
https://www.readbyqxmd.com/read/27722961/treatment-of-hypertension-which-goal-for-which-patient
#13
Faiçal Jarraya
Hypertension remains the most important risk factor for cardiovascular disease. If antihypertensive drugs choice is well guided today, blood pressure (BP) target still a subject of controversies. Residual risk is matter of debate and the lower- the better dogma is come back again regarding to data reported from recent trials. The J curve, reason for European Society of Hypertension Guidelines reappraisal in 2009, is criticized by recent data. The one goal (<140/90 mmHg) fit 90 mmg 90 mmHg) fit all should be adapted as a personalized goal guided by evidence generated by randomized controlled trials...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/27639873/isolated-systolic-hypertension-an-update-after-sprint
#14
REVIEW
Chirag Bavishi, Sangita Goel, Franz H Messerli
Isolated systolic hypertension is the most common hemodynamic form of hypertension in the elderly. With a rapidly aging population, the prevalence of hypertension, particularly isolated systolic hypertension, is expected to increase substantially. This phenomenon of increasing systolic pressure in the elderly is believed to be secondary to pathophysiological changes of aging as well as modifiable risk factors. Isolated systolic hypertension is associated with substantial mortality and morbidity, particularly of cerebrovascular disease...
December 2016: American Journal of Medicine
https://www.readbyqxmd.com/read/27619924/should-patients-with-cardiovascular-risk-factors-receive-intensive-treatment-of-hypertension-to-120-80-mm%C3%A2-hg-target-an-antagonist-view-from-the-hope-3-trial-heart-outcomes-evaluation-3
#15
https://www.readbyqxmd.com/read/27604076/comparing-the-sprint-and-the-hope-3-blood-pressure-trial
#16
Paul K Whelton, David M Reboussin, Lawrence J Fine
No abstract text is available yet for this article.
November 1, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27604060/assessing-cardiovascular-risk-to-guide-hypertension-diagnosis-and-treatment
#17
Ann Marie Navar, Michael J Pencina, Eric D Peterson
Importance: The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated the benefit of lowering systolic blood pressure (SBP) to 120 mm Hg, yet other trials, such as Heart Outcomes Prevention Evaluation-3 (HOPE-3), did not find consistent benefit. How to incorporate these results into the treatment of those with elevated SBP in the general population is not clear. Objectives: To assess the representativeness of SPRINT and HOPE-3 relative to patients in the United States and to explore the cardiovascular disease (CVD) risk profiles of various populations with elevated SBP...
November 1, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27602555/the-sprint-and-the-hope-3-trial-in-the-context-of-other-blood-pressure-lowering-trials
#18
Salim Yusuf, Eva Lonn
No abstract text is available yet for this article.
November 1, 2016: JAMA Cardiology
https://www.readbyqxmd.com/read/27598921/-pharmacological-primary-prevention-of-myocardial-infarction-stroke-and-death-a-possible-task
#19
Christian Keller, Jochen Müller-Ehmsen
The HOPE-3-Trial investigated the effect of primary prevention on cardio- and neurovascular events in patients without known atherosclerotic disease, but with intermediate risk. In a factorial design Rosuvastatin 10 mg, Candesartan 16 mg/HCT 12.5 mg or both were compared with placebo. Rosuvastatin effectively lowered LDL-cholesterol and the rate of cardio- and neurovascular complications with a NNT of approximately 500/year without detectable effect on mortalitiy. Candesartan 16 mg/HCT 12.5 mg did not influence any endpoint, however, the predefined subgroup of patients with hypertension level I had a benefit...
September 2016: Deutsche Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27521103/clinical-trials-of-intensive-versus-less-intensive-control-of-hypertension-hope-or-hype
#20
Christina M Wyatt, Glenn M Chertow
The recently published Heart Outcomes Prevention Evaluation trial (HOPE-3) demonstrated no benefit of lowering blood pressure with candesartan and hydrochlorothiazide in persons at intermediate cardiovascular risk and with adequate blood pressure control as determined by the enrolling physician. The results of Systolic Blood Pressure Intervention Trial (SPRINT) and HOPE-3 highlight the importance of considering differences in study design and patient population when interpreting the results of clinical trials...
September 2016: Kidney International
keyword
keyword
111857
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"